Fifty 410 review: pricing, fine print, and how it ranks

The price, in words

Fifty 410 advertises tirzepatide from $133 a month — a genuine, verified figure, but a starting price: no maintenance-dose figure is published anywhere we could capture, so it cannot be ranked on the same all-in 10 mg basis as the rest of the market.

What the fine print says

The published $133 figure is a starting price. No maintenance-dose figure is stated in material we could capture, so Fifty 410 cannot be ranked on the 10 mg basis every other priced program is ranked on.

Pharmacy & transparency

Price evidence: Source-verified, last verified 2026-08-05. The dispensing pharmacy is not named publicly — the single most common transparency gap in this market. Ask which pharmacy fills the prescription, whether it is 503A or 503B, and whether a certificate of analysis is available; our pharmacy guide explains what each answer means.

The dose ladder, priced rung by rung

Fifty 410 publishes a $133 starting figure and nothing above it — which is precisely the problem: the ladder's upper rungs, where treatment actually lives, have no stated price. Before enrolling, get the 10 mg and 12.5 mg all-in figures in writing; a program that won't state them is asking you to titrate into an unpriced contract.

Nearest alternatives at this price point

Shopping the immediate neighborhood, the closest verified substitutes are NexLife at $215 (flat at every dose, no membership, named pharmacy); Yucca Health at $258 (flat at every dose, no membership, prepaid to $225); IVIM Health at $278 (source-verified) — each linked matchup runs the full head-to-head arithmetic on this exact question.

State availability

Fifty 410 publishes availability of: not published. State-by-state context, exceptions, and city coverage live in the 51-state cost guides.

Five questions before checkout

Whatever the marketing says, get answers to: (1) the all-in monthly price at 10 mg and at 12.5 mg, in writing, including every mandatory fee; (2) whether the price changes at any rung of the dose ladder, and the exact tier schedule; (3) which pharmacy, by name, fills the prescription — and whether it's 503A or 503B, licensed for your state, with a certificate of analysis available; (4) the cancellation mechanics — deadline relative to renewal, written-confirmation availability, and whether any membership cancels separately. A program that answers all five plainly has already told you most of what this review can.

Visit Fifty 410 — verify current pricing →Opens the provider’s own pricing page; our figures were captured 2026-08-05.

Bottom line

Until Fifty 410 publishes verifiable pricing, treat any quoted figure as unconfirmed and get it in writing. For context, the verified market floor is $215/mo compounded tirzepatide and $133/mo compounded semaglutide, with brand Zepbound at $449/mo and Wegovy at $349/mo at maintenance.